ASCO® 2024 Insights: "QoL Data With Neoadjuvant Ipi & Nivo in Resectable Stage III Melanoma - 36-Week Data From the NADINA Trial"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "QoL Data With Neoadjuvant Ipi & Nivo in Resectable Stage III Melanoma - 36-Week Data From the NADINA Trial"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Judith Lijnsvelt

0 views

June 14, 2024

Chapters

Neoadjuvant Therapy & NADINA Trial Overview

00:00

Adverse Events & Patient Experience

02:41

Quality of Life Data & Conclusions

04:56

Comments 0

2024 ASCO® Annual Meeting Insights Hub: Skin Videos

05:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Biomarker Analysis & Updated Clinical…

Feat. L. Burton

35:23

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

Feat. S. Patel

24:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and A…

Feat. Z. Eroglu

View All

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde